)
Cosciens Biopharma (CSCI) investor relations material
Cosciens Biopharma Q3 2026 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Executive summary
Q3 revenue rose 70% YoY to $2.516M, while consolidated net loss widened to $3.445M, primarily reflecting a $2.044M PGX impairment and acquisition-related costs.
Nualtis was acquired on September 10, adding oral thin-film development and manufacturing; 20 days of its results were included in Q3.
9M net income was $7.113M, including $10.940M from discontinued operations; continuing operations recorded a $3.827M loss.
Financial highlights
Q3 revenue was $2.516M vs. $1.476M YoY; gross profit rose to $1.378M from $0.623M.
9M revenue was $7.547M vs. $5.280M; gross profit was $3.909M vs. $1.745M.
Q3 consolidated net loss was $3.445M, or $3.45 per share, vs. $1.819M and $1.72 per share; $1.1M of acquisition and financing-related professional fees contributed to higher SG&A.
9M consolidated net income was $7.113M vs. a $8.175M loss in 2025; discontinued operations contributed $10.940M of net income.
Cash and cash equivalents were $9.207M at September 30, 2026, vs. $7.307M at December 31, 2025.
Outlook and guidance
Management expects existing cash and projected operating cash flows to cover liabilities for at least 12 months, assuming debenture conversion; forecasts remain exposed to uncertain revenue and cash generation.
Liquidity forecasts assume required shareholder and TSX approvals, sufficient operating cash flows and timely payment of $6.0M deferred acquisition consideration; the debenture offering was expected to remain open through November 30, 2026.
Cost and cash-conservation measures include lower R&D spending and capex, operational restructuring, and manufacturing and procurement reviews to improve margins.
Development priorities include oat extraction improvements for avenanthramides and oat beta glucan, plus work on oat oil, protein and peptides; Rizatriptan OTF was expected to launch in Q4 2026.
- Ceapro’s growing base and Nualtis’ oral-film pipeline anchor the growth strategy.CSCI
Corporate presentation - Nualtis adds oral-film growth potential to an established natural-ingredients platform.CSCI
Corporate presentation - Q2 2026 delivered higher sales, lower expenses, and a major turnaround in profitability.CSCI
Q2 2026 - Board re-elections, auditor appointment, and share consolidation/split were all approved.CSCI
AGM 2026 - Returned to profitability in Q1 2026, driven by discontinued operations and lower expenses.CSCI
Q1 2026 - Restructuring and subsidiary exit drove lower losses and improved cost structure in 2025.CSCI
Q4 2025 - Operating expenses fell 59% and net loss narrowed in Q3 2025 amid restructuring and Nasdaq delisting.CSCI
Q3 2025 - Q2 2025 saw revenue growth, cost cuts, Nasdaq delisting, and major leadership changes.CSCI
Q2 2025 - Six directors elected, auditor reappointed, and company name change approved; no questions asked.CSCI
AGM 2024
)
)
)
)
)
)
)
)